Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD

Oliver Sartor MD

Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, Minnesota

Dr. Oliver Sartor is a medical oncologist in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Genitourinary Cancer Disease Group and the Director of Radiopharmaceutical Clinical Trials for the Mayo Clinic Comprehensive Cancer Center.

Dr. Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval of drugs for advanced prostate cancer (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and, at last count, has given invited lectures in 33 countries. He is the Medical Oncology Chair of the Genitourinary Cancer Committee of NRG, a national cancer research group.

Disclosures

  • Consultant: Advanced Accelerator Applications (AAA); Astellas; AstraZeneca; Bayer; Blue Earth Diagnostics; Bavarian Nordic; Bristol Myers Squibb; Clarity Pharmaceuticals; Clovis; Constellation; Dendreon; EMD Serono; Fusion; Isotopen Technologien Muenchen; Janssen; Merck; Myovant; Myriad; Noria Therapeutics; Novartis; Noxopharm; Progenics; POINT Biopharma; Pfizer; Sanofi; Teneobio; Telix; Theragnostics
  • Research funding: Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Constellation; Endocyte; Invitae; Janssen; Lantheus; Merck; Progenics; Teneobio

Recent Contributions to PracticeUpdate:

  1. AMG 509 (Xaluritamig) in Patients With mCRPC
  2. RADICALS RT: Timing of Adjuvant Radiotherapy Following Radical Prostatectomy
  3. ENZA-p: Enzalutamide and 177Lu–PSMA-617 in Patients With Poor-Risk mCRPC
  4. PSMAfore: 177Lu–PSMA-617 in Taxane-Naïve Patients With Metastatic Castration-Resistant Prostate Cancer
  5. Addition of Docetaxel to Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
  6. 2022 Top Story in Advanced Prostate Cancer: Efficacy of Abiraterone and Prednisolone Alone or With Enzalutamide in High-Risk Nonmetastatic Prostate Cancer
  7. PSMA-PET as a Predictive and Prognostic Tool in Patients Administered [177Lu]Lu-PSMA-617 vs Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer
  8. VISION Trial Analysis of Time-to-Event Endpoints Associated With Radioligand Therapy
  9. Androgen Annihilation in Patients With High-Risk, Biochemically Relapsed Prostate Cancer
  10. Gene-Based Confirmatory Germline Testing Following Tumor-Only Sequencing of Prostate Cancer

Most Read This Week

Recently Updated